日本药物输送设备市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

日本药物输送设备市场按给药途径(注射剂、局部、眼部和其他)、应用程序和最终用户进行细分。

市场快照

Market Snapshot1
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计日本药物输送设备市场在预测期内的复合年增长率将接近 4.5%。推动日本药物输送设备市场的主要因素是慢性病患病率的上升和技术进步。

药物输送装置有助于输送有利于目标人群更快恢复的药物。此外,日本越来越多的癌症、呼吸系统和糖尿病患者将促进药物输送设备的采用并推动整个市场。例如,根据国立癌症中心 - 癌症控制和信息服务中心的估计,2018 年日本的癌症发病率为 1,013,600 人,而最常见的癌症类型是结肠直肠癌、胃癌、肺癌、乳腺癌和前列腺癌. 因此,由于上述因素,预计将在预测期内推动市场增长。

Scope of the report

As per the scope, drug delivery devices or system are the tools which are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The Japan Drug Delivery Devices Market is segmented by route of administration, application and end user.

By Route of Administration
Injectable
Topical
Ocular
Other Route of Administration
By Application
Cancer
Cardiovascular
Diabetes
Infectious diseases
Other Applications
By End User
Hospitals
Ambulatory Surgical Centers
Other End Users

Report scope can be customized per your requirements. Click here.

主要市场趋势

通过应用,癌症预计将在预测期内出现健康增长

多年来,日本的癌症发病率和死亡率一直在上升。例如,根据世界卫生组织 (WHO) 的数据,2018 年的统计数据表明,日本死于癌症的人数增加到近 409,400 人。多年来,不断上升的死亡率一直是日本政府关注的一个因素。因此,政府和其他组织正在采取措施传播对癌症及其治疗的认识,这有望推动市场。因此,癌症患病率的上升和该国更好的研发基础设施的存在预计将在不久的将来推动市场增长。

japan key trend 1.png

竞争格局

日本药物输送设备市场竞争分散,由几个主要参与者组成。目前主导市场的一些公司包括 Mylan NV、ANTARES PHARMA, INC.、Tasei Kako Co. Ltd.、GlaxoSmithKline Plc、Novartis AG、Bayer AG、Becton、Dickinson and Company、强生和 3M 公司。

主要玩家

  1. Mylan N.V.

  2. ANTARES PHARMA, INC.

  3. Tasei Kako Co. Ltd.

  4. GlaxoSmithKline Plc

  5. Novartis AG

Japan landscape.png

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Chronic Diseases

      2. 4.2.2 Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Risk of Needlestick Injuries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Injectable

      2. 5.1.2 Topical

      3. 5.1.3 Ocular

      4. 5.1.4 Other Route of Administration

    2. 5.2 By Application

      1. 5.2.1 Cancer

      2. 5.2.2 Cardiovascular

      3. 5.2.3 Diabetes

      4. 5.2.4 Infectious diseases

      5. 5.2.5 Other Applications

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Ambulatory Surgical Centers

      3. 5.3.3 Other End Users

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Mylan N.V.

      2. 6.1.2 Antares Pharma, Inc.

      3. 6.1.3 Tasei Kako Co. Ltd.

      4. 6.1.4 GlaxoSmithKline Plc

      5. 6.1.5 Novartis AG

      6. 6.1.6 Bayer AG

      7. 6.1.7 Becton, Dickinson and Company

      8. 6.1.8 Johnson & Johnson

      9. 6.1.9 3M Company

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Japan Drug Delivery Devices Market market is studied from 2018 - 2026.

The Japan Drug Delivery Devices Market is growing at a CAGR of 4.5% over the next 5 years.

Mylan N.V., ANTARES PHARMA, INC., Tasei Kako Co. Ltd., GlaxoSmithKline Plc, Novartis AG are the major companies operating in Japan Drug Delivery Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!